Advancing the Integration of CAR T-Cell Therapy in Community Oncology Centers: Key Findings from a Transformative Quality Improvement Initiative

被引：0
|
作者：
Nawaz, M. Sarfraz [1 ]
Moses-Okwei, Ellie [2 ]
Gurska, Lindsay [2 ]
Zyborowicz, Emily [2 ]
Sullivan, Shelby [2 ]
Carter, Jeffrey [2 ]
Heggen, Cherilyn [2 ]
机构：
[1] Hematol Oncol Indiana, Carmel, IN USA
[2] PRIME Educ, New York, NY USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203606
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7594 / 7595
页数：2
相关论文
共 50 条
  • [41] Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy
    Shah, Nirali N.
    Qin, Haiying
    Yates, Bonnie
    Su, Ling
    Shalabi, Haneen
    Raffeld, Mark
    Ahlman, Mark A.
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Guo, Shuang
    Liu, Siyuan
    Hughes, Stephen H.
    Fry, Terry J.
    Wu, Xiaolin
    BLOOD ADVANCES, 2019, 3 (15) : 2317 - 2322
  • [42] Sleeping Beauty (SB) Transposition Integration Events Mediated by SB Transposase from mRNA and CAR from SB DNA for T-Cell Therapy
    Maiti, Sourindra
    Torikai, Hiroki
    Zhang, Ling
    Yan, Yuanqing
    Wei, Wei
    Olivares, Simon
    Moriarity, Branden
    Largaespada, David
    Huls, Helen
    Cooper, Laurence
    MOLECULAR THERAPY, 2017, 25 (05) : 41 - 42
  • [43] Should Transplant Centers Prioritize Further Stem Cell Collection for Future CAR T-Cell Therapy Boosts? an Economic and Clinical Assessment
    Malek, Ehsan
    Davila, Marco
    Tirado, Hector
    Holtan, Shernan G.
    Betts, Brian
    Yu, Han
    BLOOD, 2024, 144 : 7252 - 7253
  • [44] EXPERIENCES WITH AND PERCEPTIONS OF CAR T-CELL THERAPY FOR MULTIPLE MYELOMA AMONG COMMUNITY-BASED HEMATOLOGISTS/ONCOLOGISTS
    Gentile, D.
    Jeune-Smith, Y.
    Klink, A.
    Feinberg, B.
    Gajra, A.
    VALUE IN HEALTH, 2022, 25 (07) : S588 - S588
  • [45] Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024
    Haixiao Zhang
    Hong-Hu Zhu
    Experimental Hematology & Oncology, 14 (1)
  • [46] A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial
    Mayor, Marissa
    Zeltsman, Masha
    McGee, Erin
    Adusumilli, Prasad S.
    IMMUNOTHERAPY, 2016, 8 (05) : 491 - 494
  • [47] Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study
    Mayo, Samantha J.
    Edelstein, Kim
    Bernstein, Lori
    Coley, Tiana
    Morrison, Stacey
    Vijenthira, Abi
    Maganti, Manjula
    Kuruvilla, John
    Crump, Michael
    Bhella, Sita D.
    Kridel, Robert
    Kukreti, Vishal
    Yang, Chloe
    Alibhai, Shabbir M. H.
    Chen, Christine
    Prica, Anca
    BLOOD, 2023, 142
  • [48] A REAL-WORLD ANALYSIS OF CAR T-CELL CANCELLATIONS FROM A CANADIAN CELL THERAPY REFERRAL CENTRE
    Al-Shaibani, Eshrak
    Bautista, Rhida
    Atenafu, Eshetu
    Winter, Andrew
    Prica, Anca
    Crump, Michael
    Kuruvilla, John
    Kukreti, Vishal
    Kridel, Robert
    Law, Arjun
    Pasic, Ivan
    Saibil, Sam
    Lam, Wilson
    Bhella, Sita
    Chen, Christine
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 202 - 203
  • [49] Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
    Dhawale, Tejaswini
    Johnson, P. Connor
    Gaballa, Mahmoud R.
    Nelson, Ashley
    Lavoie, Mitchell W.
    Frigault, Matthew
    Boateng, Kofi
    Greydanus, Claire
    El-Jawahri, Areej
    BLOOD, 2022, 140 : 10989 - 10990
  • [50] Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management
    Rejeski, Kai
    Jain, Michael
    Shah, Nirali N.
    Perales, Miguel-Angel
    Subklewe, Marion
    LANCET HAEMATOLOGY, 2024, 11 (06): : e459 - e470
12345